VRNA Verona Pharma plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRNA

Price (delayed)

$15.69

Market cap

$1.27B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.72

Enterprise value

$1.05B

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, ...

Highlights
Verona Pharma's quick ratio has surged by 161% YoY and by 9% QoQ
The EPS has grown by 31% year-on-year but it has declined by 29% since the previous quarter
VRNA's net income is up by 21% YoY but it is down by 7% QoQ
The debt has soared by 153% since the previous quarter
Verona Pharma's revenue has plunged by 100% from the previous quarter and by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.veronapharma.com
Peers: NWBO

Key stats

What are the main financial stats of VRNA
Market
Shares outstanding
80.82M
Market cap
$1.27B
Enterprise value
$1.05B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.03
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$51.84M
EBITDA
-$51.16M
Free cash flow
-$50.22M
Per share
EPS
-$0.72
Free cash flow per share
-$0.63
Book value per share
$3.12
Revenue per share
$0
TBVPS
$3.88
Balance sheet
Total assets
$308.12M
Total liabilities
$58.84M
Debt
$51.33M
Equity
$249.28M
Working capital
$281.02M
Liquidity
Debt to equity
0.21
Current ratio
33.33
Quick ratio
31.27
Net debt/EBITDA
4.31
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-17.7%
Return on equity
-20.5%
Return on invested capital
-108.2%
Return on capital employed
-17.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRNA stock price

How has the Verona Pharma stock price performed over time
Intraday
-0.38%
1 week
1.42%
1 month
-3.33%
1 year
-25.96%
YTD
-21.08%
QTD
-2.49%

Financial performance

How have Verona Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$67.57M
Net income
-$54.37M
Gross margin
N/A
Net margin
N/A
Verona Pharma's revenue has plunged by 100% from the previous quarter and by 100% YoY
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
VRNA's net income is up by 21% YoY but it is down by 7% QoQ
The operating income has grown by 11% YoY but it has contracted by 6% from the previous quarter

Growth

What is Verona Pharma's growth rate over time

Valuation

What is Verona Pharma stock price valuation
P/E
N/A
P/B
5.03
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 31% year-on-year but it has declined by 29% since the previous quarter
VRNA's P/B is 62% above its 5-year quarterly average of 3.1 but 13% below its last 4 quarters average of 5.8
VRNA's equity is up by 8% year-on-year but it is down by 5% since the previous quarter
Verona Pharma's revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Verona Pharma business performance
The ROIC has soared by 79% YoY and by 24% from the previous quarter
Verona Pharma's ROE has increased by 47% YoY but it has decreased by 6% from the previous quarter
Verona Pharma's ROA has increased by 45% YoY but it has decreased by 2.9% from the previous quarter

Dividends

What is VRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRNA.

Financial health

How did Verona Pharma financials performed over time
Verona Pharma's quick ratio has surged by 161% YoY and by 9% QoQ
Verona Pharma's current ratio has soared by 161% YoY and by 9% from the previous quarter
The debt is 79% smaller than the equity
Verona Pharma's debt to equity has surged by 163% QoQ
The debt has soared by 153% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.